Clinical Trials Browser

Interventional × Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × 90 days × Clear all

NCT07241416 2026-01-30

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Recruiting

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)